Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Seasonal Influenza Vaccines Report Overview

In the 7MM, there were 1,491,549 diagnosed incident cases of seasonal influenza vaccines in 2022. The diagnosed incident cases of seasonal influenza vaccines are expected to register a negative AGR of less than 1% during 2022-2032. Seasonal influenza (SI) is a contagious respiratory viral illness. There are four types of SI viruses: A, B, C, and D; however, only types A and B cause human disease of public health concern (WHO, 2023). Influenza transmission occurs when people with the flu cough, sneeze, or talk, thereby disseminating droplets. These droplets can land in the mouths or noses of people who then inhale them into the lungs (CDC, 2022).

Symptoms of influenza are headache, fever, cough, sore throat, and aching muscles and joints. The influenza virus tends to cause more severe disease in infants, elderly people, young children, and those with a weakened immune system (WHO, 2023).

Seasonal Influenza Vaccines Market Outlook, 2022-2032 (Diagnosed Incident Cases)

Seasonal Influenza Vaccines Market Outlook, 2022-2032 (Diagnosed Incident Cases)

Buy the Full Report for More Insights into the Seasonal Influenza Vaccine Market Forecast

Download a Free Report Sample

The Seasonal influenza vaccines market research report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for seasonal influenza vaccines in the seven major markets namely the US, France, Germany, Italy, Spain, UK, and Japan. The report also includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of seasonal influenza.

Market Size (2022) 1,491,549 Cases
AGR (2022-2032) >(1)%
Forecast Period 2023 – 2032
Key Countries ·        The US

·        France

·        Germany

·        Spain

·        Italy

·        The UK

·        Japan

Key Sex Segments ·        Men

·        Women

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Seasonal Influenza Vaccines Market Segmentation by Country

The key countries across the 7 MM are the US, France, Germany, Spain, Italy, the UK, and Japan. The US had the highest number of diagnosed incident cases of seasonal influenza vaccines in 2022. However, the UK is expected to see the largest increase in diagnosed incident cases of lab-confirmed SI out of all the 7MM by 2032.

Seasonal Influenza Vaccines Market Analysis by Country, 2022 (%)

Seasonal Influenza Vaccines Market Analysis by Country, 2022 (%)

Buy the Full Report for More Country Insights into the Seasonal Influenza Vaccine Market

Download a Free Report Sample

Seasonal Influenza Vaccines Market Segmentation by Sex

Based on sex, the seasonal influenza vaccine market can be segmented into men and women. In 2022, the number of diagnosed incident cases of seasonal influenza vaccines was higher in women than in men in the 7MM combined. In all markets, slightly more women were diagnosed than men except in the UK.

Seasonal Influenza Vaccines Market Analysis by Sex, 2022 (%)

Seasonal Influenza Vaccines Market Analysis by Sex, 2022 (%)

Buy Full Report for More Sex Insights into the Seasonal Influenza Vaccines Market

Download a Free Report Sample

Segments Covered in the Report

Seasonal Influenza Vaccines Market Country Outlook (Diagnosed Incident Cases, 2022-2032)

  • The US
  • France
  • Germany
  • Spain
  • Italy
  • The UK
  • Japan

Seasonal Influenza Vaccines Market Sex Outlook (Diagnosed Incident Cases, 2022-2032)

  • Men
  • Women

Scope

  • Seasonal Influenza (SI) vaccine Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza-like illness (ILI), and lab-confirmed SI segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years). Seasonal Influenza (SI) vaccine Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of SI in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of influenza-like illness (ILI), and lab-confirmed SI segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years) and sex. The report also includes a 10-year epidemiological forecast for the SI vaccinated population segmented by age (0–4 years, 5–17 years, 18–64 years, and ≥65 years).
  • The Excel model accompanying this report includes lab-confirmed SI mortality, diagnosed incident cases of SI averted by vaccination, SI-related hospitalized cases, hospitalization averted by SI vaccination, and cases of ILI and lab-confirmed SI in third-trimester pregnant women.

Reasons to Buy

The seasonal influenza vaccines epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global seasonal influenza vaccines market.
  • Quantify patient populations in the global seasonal influenza vaccine market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for seasonal influenza vaccine therapeutics in each of the markets covered.

Table of Contents

  • 1. Seasonal Influenza Vaccines: Executive Summary

    • 1.1. Catalyst
    • 1.2. Related Reports
    • 1.3. Upcoming Reports

  • 2. Epidemiology

    • 2.1. Disease background
    • 2.2. Risk factors and comorbidities
    • 2.3. Global and historical trends
    • 2.4. 7MM forecast methodology.

      • 2.4.1. Sources
      • 2.4.2. Forecast assumptions and methods.
      • 2.4.3. Forecast assumptions and methods: diagnosed incident cases of ILI
      • 2.4.4. Forecast assumptions and methods: diagnosed incident cases of lab-confirmed SI.
      • 2.4.5. SI vaccinated population

    • 2.5. Epidemiological forecast for ILI, lab-confirmed SI, and SI vaccinated population (2022–32)

      • 2.5.1. Diagnosed incident cases of ILI.
      • 2.5.2. Age-specific diagnosed incident cases of ILI
      • 2.5.3. Sex-specific diagnosed incident cases of ILI
      • 2.5.4. Diagnosed incident cases of lab-confirmed SI
      • 2.5.5. Age-specific diagnosed incident cases of lab-confirmed SI
      • 2.5.6. Sex-specific diagnosed incident cases of lab-confirmed SI
      • 2.5.7. SI vaccinated population
      • 2.5.8. Age-specific SI vaccinated population

    • 2.6. Discussion

      • 2.6.1. Epidemiological forecast insight
      • 2.6.2. COVID-19 impact.
      • 2.6.3. Limitations of the analysis
      • 2.6.4. Strengths of the analysis

  • 3. Appendix

    • 3.1. Bibliography
    • 3.2. About the Authors

      • 3.2.1. Epidemiologist
      • 3.2.2. Reviewers
      • 3.2.3. Vice President of Disease Intelligence and Epidemiology

  • 4. Contact Us

Table

Table 1: Summary of updated data types

Table 2: Risk factors and comorbidities for SI

Figures

Figure 1: 7MM, diagnosed incident cases of lab-confirmed influenza, both sexes and all ages, N, 2022 and 2032

Figure 2: 7MM, SI vaccinated cases, both sexes and all ages, N, 2022 and 2032

Figure 3: 7MM, diagnosed incidence of lab-confirmed SI, both sexes, cases per 100,000 population, all ages, 2012–32

Figure 4: 7MM, SI vaccination rate, both sexes, %, all ages, 2012–32

Figure 5: 7MM, sources used to forecast diagnosed incident cases of ILI

Figure 6: 7MM, sources used to forecast diagnosed incident cases of lab-confirmed SI

Figure 7: 7MM, sources used in SI vaccinated population

Figure 8: 7MM, diagnosed incident cases of ILI, N, both sexes, all ages, 2022

Figure 9: 7MM, diagnosed incident cases of ILI by age, N, both sexes, 2022

Figure 10: 7MM, diagnosed incident cases of ILI by sex, N, all ages, 2022

Figure 11: 7MM, diagnosed incident cases of lab-confirmed SI, N, both sexes, all ages, 2022

Figure 12: 7MM, diagnosed incident cases of lab-confirmed SI by age, N, both sexes, 2022

Figure 13: 7MM, diagnosed incident cases of lab-confirmed SI by sex, N, all ages, 2022

Figure 14: 7MM, SI vaccinated population, N, both sexes, all ages, 2022

Figure 15: 7MM, SI vaccinated population by age, N, both sexes, 2022

Frequently asked questions

Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032 in real time.

  • Access a live Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.